Clinical Trials Information
As a biopharmaceutical company, Nektar conducts preclinical and clinical studies on our investigational drug candidates to evaluate our products for safety and efficacy. Nektar is developing a number of investigational drug candidates to target debilitating conditions or diseases. The company focuses its efforts on medical conditions where we believe current drugs are not providing optimal therapeutic benefit.
Before a new therapeutic can be made available to the general public, rigorous tests involving multiple studies on human volunteers are required. These studies, referred to as clinical trials, are carefully conducted and regulated by the Food and Drug Administration (FDA) in the United States, and by similar regulatory agencies worldwide. Participation in clinical trials allows patients to potentially gain access to the latest investigational treatments at no cost, and play an important role in advancing medicine.
Nektar Therapeutics is currently recruiting patients in the U.S. and other countries for the following clinical trials. Please follow the links below for more information on the enrollment criteria for each study and site locations:
More information on naloxegol (NKTR-118) »
More information on Etirinotecan pegol (NKTR-102) »
Further information and background on clinical trials may be found on www.clinicaltrials.gov, a service of the U.S. National Institutes of Health (NIH).